Head and Neck Cancer
An Introduction to Head and Neck Cancer
More than 60% of patients with squamous cell cancer of the head and neck present with stage III or IV disease, which has a poor prognosis. However, recent advances have improved outcomes. Chemoradiotherapy is often successful in first-line treatment and more precisely targeted radiotherapy using intensity-modulated radiation therapy, molecular imaging-guided therapy, adaptive therapy and proton beam therapy is expected to decrease the long-term toxicity of radiotherapy. However, recurrent or metastatic disease often develops. Immune checkpoint inhibitors targeting programmed death ligand 1 (PD-L1) have proved effective for a minority of patients in this setting and are being investigated in earlier treatment settings.
Expert video highlights, insights from the conference hub and comprehensive peer-reviewed articles from our journal portfolio provide updates on the changing treatment landscape. To learn more about how the latest developments impact on patient outcomes view our expert-led learning activities.
